Atenção obstétrica no Reino Unido durante pandemia

Publicado no Best Practice & Research Clinical Obstetrics & Gynaecology

2. Labour and birth

Highlights

Infection prevention and control in intrapartum care is a priority.
Women who become unwell with COVID-19 are at higher risk of iatrogenic preterm birth and have higher than normal rates of caesarean section.
Maintaining choice of place of birth, providing high quality care and support and pain relief should also remain a priority.
Care should be taken to enable women to have access to their partner or support person and remain with their newborn.

Abstract

This chapter describes the national guidance for care during labour and childbirth in the United Kingdom during the COVID-19 pandemic. The content largely draws attention on the guidance developed by the Royal College of Obstetricians (RCOG) and the Royal College of Midwives (RCM), and specific guidance on infection prevention and control measures from Public Health England.

The key areas addressed are as follows:

Testing of pregnant women before and on admission for labour and birth
Overall approach to intrapartum care for women with and without symptoms of COVID-19
Timing, place, and type of birth considerations
Personal Protective Equipment (PPE) during labour and birth – for staff, women, and birth supporters
Use of birthing pools and waterbirth
Foetal monitoring
Immediate care of the newborn and support for breastfeeding.

The chapter refers to some of the ways in which the guidance was translated in practice.

The guidance was developed using a rapid analysis approach to emerging research and evidence, along with evidence from previous experiences of coronavirus combined with consensus expert opinion from all key professionals providing maternity care in the UK.

What is known

The UK RCOG/RCM COVID-19 guidance was widely accepted across the UK maternity services and also worldwide as a reliable and credible source of information to shape care during the pandemic.

What is not known

The full impact of the pandemic on the experiences and outcomes for babies and women of pregnancy, childbirth, and early parenting in the UK.

The impact of the new approaches to intrapartum care on experiences and outcomes for women, babies, and families.

The impact of the changes required to intrapartum care as a result of the pandemic on the professional care provided; in terms of pressure created by rapidly changing approaches to care and restrictions on the ability to provide normal levels of care.

Keywords

COVID-19
Pandemic
Intrapartum care
Foetal monitoring
Waterbirth
Skin to skin

Pregnant women’s appetite for risk

CORRESPONDENCE| VOLUME 9, ISSUE 5E593, MAY 01, 2021

Pregnant women’s appetite for risk

Open AccessPublished:March 02, 2021DOI:https://doi.org/10.1016/S2214-109X(21)00044-9
Historically, pregnant and lactating women have been considered vulnerable groups, which is used as an ongoing justification for their exclusion from clinical trials. Melanie Taylor and colleagues (February, 2021) argue that pregnant women, who already face increased risk of adverse outcomes from COVID-19, will be doubly disadvantaged if unable to access treatments due to a lack of safety and efficacy evidence. This concern extends to vaccinations, and a review of WHO-registered COVID-19 clinical trials found that all nine vaccine trials explicitly excluded pregnant women. In the UK, both pregnant and lactating women were initially excluded from receiving COVID-19 vaccines. A policy U-turn followed a month later and, although welcome, it confused clinicians and the public. Anecdotal evidence is emerging of pregnant women in the UK and the USA who are willing to be vaccinated. These decisions could be influenced by an individual’s personal risk assessment of high exposure to COVID-19, their underlying health conditions, or because they perceive that known benefits of vaccination outweigh theoretical risks. If the aim of excluding pregnant and lactating women from trials is to protect them and their babies from unknown harm, this is failing. Experimentation has merely shifted to the poorly controlled setting of real-world implementation.
In this real-world setting, a pertinent question is who should carry the experimentation risk? It is unclear whether responsibility lies with the pharmaceutical industry, which has historically avoided ownership of the problem. If not, risk lies between regulators or public health bodies producing immunisation guidelines, medical practitioners who must discuss risk–benefit decisions with patients (without data to inform this discussion), and pregnant women themselves. This risk shifting could lead to further inequities, variation in care, and vaccine misconceptions.
To facilitate ethical and just inclusion of pregnant women in clinical trials, we support the 22 recommendations made by the PREVENT Working Group, and propose a further two after observing the UK’s COVID-19 vaccine rollout: (1) pregnant and lactating women must be considered separately (as in the recent WHO guideline), and receive tailored risk assessments and recommendations; and (2) women, families, and communities globally must be consulted about specific safeguards that would increase their ability and willingness to participate in clinical trials while pregnant or lactating.
The research community maintains a complacent and unsubstantiated assumption that pregnant women have a low appetite for risk. The COVID-19 pandemic has shown that default exclusion cannot continue, and we as a global research community must prioritise gender equity when producing evidence that underpins clinical recommendations.
We declare no competing interests. AV and KW contributed equally.

References

  1. 1.
    • Taylor MM
    • Kobeissi L
    • Kim C
    • et al.
    Inclusion of pregnant women in COVID-19 treatment trials: a review and global call to action.

    Lancet Glob Health. 2020; (published online Dec 16.)

  2. 2.
    • Smith DD
    • Pippen JL
    • Adesomo AA
    • Rood KM
    • Landon MB
    • Costantine MM
    Exclusion of pregnant women from clinical trials during the coronavirus disease 2019 pandemic: a review of international registries.

    Am J Perinatol. 2020; 37792

  3. 3.
    • Cirruzzo C
    In absensce of data, pregnant women push forward with COVID-19 vaccine. US News.
  4. 4.
    • Farrell R
    • Michie M
    • Pope R
    Pregnant women in trials of Covid-19: a critical time to consider ethical frameworks of inclusion in clinical trials.

    Ethics Hum Res. 2020; 4217-23

  5. 5.
    • Krubiner CB
    • Faden RR
    • Karron RA
    • et al.
    Pregnant women & vaccines against emerging epidemic threats: ethics guidance for preparedness, research, and response.

    Vaccine. 2021; 3985-120

Coronavirus Disease 2019 (COVID-19)–Related Multisystem Inflammatory Syndrome in a Pregnant Woman

CONTENTS: CASE REPORT

Coronavirus Disease 2019 (COVID-19)–Related Multisystem Inflammatory Syndrome in a Pregnant Woman

Gulersen, Moti MD, MSc; Staszewski, Cara MD; Grayver, Evelina MD; Tam Tam, Hima MD; Gottesman, Eric MD; Isseroff, Donnie MD; Rochelson, Burton MD; Bonanno, Clarissa MD

Author Information

doi: 10.1097/AOG.0000000000004256


BACKGROUND:

Recent reports have described a rare but severe complication of coronavirus disease 2019 (COVID-19) in nonpregnant adults that is associated with extrapulmonary organ dysfunction and appears to be secondary to a hyperinflammatory state.

CASE:

A multiparous woman at 28 weeks of gestation, diagnosed with COVID-19 4 weeks prior, was admitted with chest pain. Evaluation indicated myocarditis and marked elevations of inflammatory markers consistent with multisystem inflammatory syndrome in adults. The patient developed cardiogenic shock and required mechanical ventilation. Treatment with intravenous immunoglobulin and high-dose corticosteroids was associated with a favorable maternal and fetal outcome.

CONCLUSION:

Multisystem inflammatory syndrome in adults associated with COVID-19 in pregnancy is a critical illness, presenting several weeks after initial infection. Treatment with intravenous immunoglobin and corticosteroids was associated with a favorable outcome.

Pregnancy-associated deaths will increase in the COVID-19 era

Maternal mortality due to partner violence, suicide, and substance overdoses will increase due to COVID-19.

Do blog da Maternal Health Task Force

 

By: Kathryn Mishkin, DrPH, MPH, MA, Associate Director of Evaluation, March of Dimes; Rahul Gupta, MD, MPH, MBA, FACP, Chief Medical & Health Officer, SVP, March of Dimes; Roland Estrella, MS, MBA, Senior Director of Science, Data, and Evaluation, March of Dimes

 

COVID-19 has devastated the lives of the American people with over 250,000 deaths to date, and this impact is going to extend to pregnant and postpartum women.

This is terrifying considering that the United States entered the pandemic with the infamous status of having the highest maternal mortality rate among all developed nations. Already, researchers are concerned about an increase in maternal morbidity and mortality due to COVID-19’s effect on pregnant women’s immune systems, its contribution to cardiopulmonary complications, and the higher rates of hospitalizations and ICU visits among pregnant women with COVID. It is feared that Black women will be particularly affected, and this is troubling considering that Black women were already four times more likely to die in the maternal period compared to White women pre-COVID.

It is clear that COVID-19 will adversely affect pregnant and postpartum women’s physical health.

However, current predictions have not yet painted a full picture of how COVID-19 may contribute to an increase in maternal mortality in the United States. It is essential that we expand our discussion beyond medical causes of death to include maternal deaths due to suicide, substance overdose, and homicide as a result of partner violence.

We expect pregnant and postpartum women to die more frequently from these causes because we are seeing this happen in the general population. Since January, drug overdoses have spiked according to the Office of National Drug Control Policy. A physician in California says he has seen more deaths from suicide than COVID-19, with a year’s worth of suicide deaths occurring in just four weeks. The United Nations Population Fund predicts IPV rates will increase by 20% during a three-month quarantine. Physical distancing, while protective against COVID-19, exacerbates the risk of being abused and suffering from mental illness because of social isolation and increased stress. From a social perspective, women are now facing the brunt of increased responsibility for domestic responsibilities that comes with the “new normal”, and this added stress will have an impact on their health.

Furthermore, we know that pregnant and postpartum women were dying from these causes before the pandemic. A global study revealed that 13-36% of maternal deaths are due to suicide. In 2016, Philadelphia’s maternal mortality review reported that nearly half of pregnancy-associated deaths were due to injuries including homicide, suicide, and drug overdoses. In California, research shows that drug-related and suicide deaths are the second and seventh leading cause of maternal deaths, respectively, constituting 18% of all maternal deaths.

We also know that certain populations are at higher risk for these types of deaths. People living with underlying mental illness are at higher risk for dying from suicide and substance overdose deaths and women experiencing IPV are more likely to have a mental illness. Measures taken to limit the spread of the virus will result in reduced access to and use of care and support for some at-risk populations.

In sum, pregnant and postpartum women were already experiencing IPV, suffering from mental illness, and using substances, and COVID-19 will exacerbate these issues.

We call on public health leaders to join the #Blanket Change movement to raise awareness about the urgent health crisis moms and babies are facing in order to ramp up prevention and care and support documentation of these deaths.

Prevention of death due to these causes is possible but requires an effective and efficient health care and social support system. The American College of Obstetricians and Gynecologists provides recommendations for screening for substance use, IPV, and depression. In spite of this, screening appears to be lacking. For example, a recent report by the Centers for Disease Control and Prevention stated that 20% of women were not asked by their health care provider about depression symptoms in the prenatal period and 12.5% were not asked in the postpartum period, with a wide discrepancy in rates depending on where a woman was living.  We call on health care providers to improve screening for mental illness, IPV, and substance use to improve the health of moms and babies.

In addition to effective prevention, we call for all states to document the frequency of deaths due to suicide, IPV, and substance overdose through maternal mortality review.  Full documentation on a national scale will allow us to develop a better understanding of the reasons that pregnant and postpartum women are dying. Without a comprehensive review, our ability to develop critical recommendations to prevent future deaths will remain inadequate.

LONG-COVID IN CHILDREN – PARENTS AND FAMILIES’ PERSPECTIVES NEED TO BE HEARD

Long-COVID in Children – Parents and families’ perspectives need to be heard

Frances Simpson is a founding member of LongCovidKids and LongCovidSOS and a Lecturer in Psychology at Coventry University. She is on Twitter: @FrancesorFran

Carolyn Chew-Graham is a GP in Central Manchester and Professor of General Practice Research at Keele University; Carolyn’s main areas of interest include the primary care management of people with multiple health conditions and difficult to understand symptoms which are key components of her clinical work. She is on Twitter: @CizCG

Amali Lokugamage is a consultant in obstetrics and gynaecology, and honorary associate professor and currently has long covid. She is on Twitter: @Docamali

PARENTS HAVE BEEN STRUGGLING to obtain help and support, watching their children with persistent symptoms following acute infection with COVID-19. Early on in the pandemic, parents and children felt they were disbelieved by their general practitioners (GPs) as they witnessed an emerging phenomenon. As ‘Long-COVID’ came to be recognised in adults1 and named as such by patients2 there came to be a growing acceptance that Long-COVID can also occur in children as evidence emerged.3 Indeed, ONS statistics suggest that 12-15% of children may have symptoms lasting 5 weeks after an acute infection with COVID-19.

12-15% of children may have symptoms lasting 5 weeks after an acute infection with COVID-19.

The lack of GP awareness has led to some parents whose children have long-COVID feeling that their children’s symptoms were minimised or even ‘gaslighted’; experiences that were highlighted in the recent All Party Parliamentary Group (APPG) about Long Covid in children on 26th January 2021. Parents described desperation and fear of seeking further help, not wanting to be branded with the stigma of ‘Munchausen by proxy’. While the adult population of Long-COVID sufferers were assembling on social media groups and collecting data, children were discounted under the misconception that children did not get COVID severely, that they did not transmit COVID, that they were often asymptomatic.4 Even when the facts of paediatric inflammatory multisystem syndrome temporally associated with COVID-19 (PIMS-TS) in children started to present themselves,5 it was understood that this was very rare. When parents started to wonder why their children were becoming ill from COVID and not making a full recovery, there was no narrative in existence that helped them to make sense of this.

Parents described desperation and fear of seeking further help.

Through desperation, mothers Frances Simpson and Sammie McFarland, whose children became sick in March 2020, joined forces to start the support group LongCovidKids. These families found themselves in a confusing place of being told that there was no proof that their childrens’ symptoms were a result of COVID, due to the lack of testing available in Spring 2020. LongCovidKids has evolved to provide support for families with Long-COVID; this now has 940 parents or carers, many of whom have more than one child with Long-COVID. Symptoms described by members of the group range from the most common symptoms of fatigue, headache, abdominal pain, dizziness and muscle pain to the most frightening to parent – electric shock-like pain in the eyes and head, nerve pain, testicular pain, liver damage, paralysis and new-onset seizures; some of their experiences are captured in a film.

Parents have noted that their children are also affected by anxiety, OCD and extremely volatile mood changes which may be associated with neuro-inflammatory processes6 as well as a natural response to being so unwell. The majority of parents would describe their child’s symptoms as fluctuating, and many describe a gap of many weeks between the acute stage and the start of Long-COVID. This variability causes further confusion when presenting the problems to a GP and often leads to diagnoses of anxiety or symptoms attributed to the effects of lockdown or home-schooling.

Children are also affected by anxiety, OCD and extremely volatile mood changes which may be associated with neuro-inflammatory processes.

The combination of an often mild or asymptomatic acute illness, followed by delayed debilitating symptoms of Long-COVID, lack of testing and limited awareness amongst GPs about the syndrome has meant that in the UK it is currently difficult to assess the prevalence of Long-COVID in children. The ONS data has now given us some estimation and the recent European data helps to validate this emerging condition in children.3

NHS England now recognises that Long COVID in children needs urgent evaluation and as this official recognition, epidemiological evidence and long-COVID paediatric services evolve, it is hoped that GPs will be provided the resources they need to support families where children are affected by Long-COVID.

In consultations with parents and children, it is preferable to admit to the limitations of knowledge, whilst being interested in the experiences of the family, believing in presented problems and offering support, help and referral. Parents who are frightened for their child need to feel listened to, and the child needs their experiences to be validated. After all, their lived experiences are also valuable evidence.

 

References

  1. Greenhalgh T, Knight M, A’Court C, Buxton M, Husain L. Management of post-acute covid-19 in primary care. BMJ2020;370:m3026. doi:10.1136/bmj.m3026 pmid:32784198
  2. Body Politic COVID-19 Support Group. Report: what does covid-19 recovery actually look like? 2020. https://patientresearchcovid19.com/research/report-1/
  3. Buonsenso D, Munblit D, De Rose C et al; Preliminary Evidence on Long COVID in children. medRxiv 2021.01.23.21250375; doi: https://doi.org/10.1101/2021.01.23.21250375
  4. Zimmermann P, Curtis N. Why is COVID-19 less severe in children? A review of the proposed mechanisms underlying the age-related difference in severity of SARS-CoV-2 infectionsArchives of Disease in Childhood Published Online First: 01 December 2020. doi: 10.1136/archdischild-2020-320338
  5. Harwood R, Allin B, Jones CE et al; PIMS-TS National Consensus Management Study Group. A national consensus management pathway for paediatric inflammatory multisystem syndrome temporally associated with COVID-19 (PIMS-TS): results of a national Delphi process. Lancet Child Adolesc Health. 2021 Feb;5(2):133-141. doi: 10.1016/S2352-4642(20)30304-7. Epub 2020 Sep 18. Erratum in: Lancet Child Adolesc Health. 2021 Feb;5(2):e5. PMID: 32956615; PMCID: PMC7500943.
  6. Mazza MG, De Lorenzo R, Conte C et al; COVID-19 BioB Outpatient Clinic Study group, Benedetti F. Anxiety and depression in COVID-19 survivors: Role of inflammatory and clinical predictors. Brain Behav Immun. 2020 Oct;89:594-600. doi: 10.1016/j.bbi.2020.07.037. Epub 2020 Jul 30. PMID: 32738287; PMCID: PMC7390748.

 

Featured photo by Kat J on Unsplash

Research Update on COVID-19 and Pregnancy

Da Newsletter da Evidence Based Birth

 

Hello

It’s been 6 weeks since our last COVID-19 and pregnancy newsletter.

In this edition of the Evidence Based Birth® COVID-19 Newsletter, we provide a new overview of the research on COVID-19 and pregnancy to date, focusing on key findings and recommendations.

**Feel free to forward this email to any friends, family, clients, or colleagues who might find it helpful. If you’re a healthcare worker, feel free to print this off to share at the nurse’s station! Anyone can subscribe to receive these updates by visiting evidencebasedbirth.com/covid19

The archive of this newsletter will also be posted on that page.

Today’s questions (answered in a Q&A section at the bottom of this email) include:

  • Do we know what the overall pre-term birth rate was in the U.S. for 2020, and how that might compare to other years?
  • I have a history of COVID in early pregnancy, and now my doctor is recommending that I take either aspirin or an anticoagulant for the rest of pregnancy. Is there any research on this?

To ask a question for consideration for future newsletters, submit your question here.

Don’t forget that our COVID-19 resource & pregnancy page includes archives of these newsletters (including past Q & A’s), a sample informed consent form to refuse mother-newborn separation, our virtual doula directory, a free birthing crash course, a link to find our comprehensive EBB Childbirth Class online, and other info you might find useful. You can access that page here.


Research Update for January 21, 2021

  • Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the virus that causes coronavirus disease 2019 (COVID-19).
  • Black, Latinx, and Indigenous pregnant and nonpregnant individuals are bearing the burden of the pandemic. These groups have higher rates of COVID-19 infections, hospitalizations, and severe outcomes, including death. Racial and ethnic health inequity in the pandemic is due to long-standing structural racism that put brown and black bodies at increased risk of getting sick and dying—not because of their biology, but because of discrimination in all sectors of life (aka systemic racism).

Numbers Update from Johns Hopkins University

As of January 21, 2021, there are over 96 million confirmed and probable cases of COVID-19 around the world. The highest number of cases is still in the U.S. (over 24 million), followed by India, Brazil, Russia, the United Kingdom, France, Italy, Turkey, Spain, and Germany.

Prevention

  • Pregnant people are advised to follow the same recommendations as nonpregnant people for avoiding exposure to SARS-CoV-2. These recommendations from the CDC include:
    • Wear a mask over your nose and mouth
    • Stay 6 feet away from people who don’t live in your household
    • Avoid crowded places
    • Meet in outdoor spaces when possible and try to ventilate indoor spaces
    • Wash hands often
    • Cover coughs and sneezes
    • Clean and disinfect frequently touched surfaces
    • Be alert for symptoms of COVID-19
  • Prenatal and postpartum care appointments are important to keep; however, depending on your individual circumstances, it might be appropriate to delay some appointments or meet virtually. Elective ultrasounds are not recommended (ACOG, 2020). GBS screening is still recommended between 36 weeks, 0 days and 37 weeks, 6 days of pregnancy. However, some care settings are giving people instructions on how to self-collect a vaginal-rectal swab to limit in-person exposure during the pandemic (ACOG, 2020).

Vaccines

  • Many vaccines are being developed, but pregnant and lactating individuals have been excluded from every trial so far. This means we do not have any data yet on the maternal, fetal, or newborn effects of these vaccines.
  • The two vaccines that are currently authorized and recommended to prevent COVID-19 in the U.S. are the Pfizer-BioNTech vaccine and Moderna’s vaccine. They are both messenger RNA (mRNA) vaccines that do not contain live virus.
  • In the U.S., the SMFM (12/21), ACOG (12/21), and the CDC (12/28) recommended that COVID-19 vaccines should not be withheld from pregnant/lactating individuals who are otherwise eligible for the vaccine and desire vaccination.
  • In the U.K., on December 3, the Joint Committee on Vaccination and Immunization initially stated “JCVI favours a precautionary approach, and does not currently advise COVID-19 vaccination in pregnancy.” However, the JCVI updated their guidance on December 30 and now advises that “extremely clinically vulnerable” pregnant people discuss the option of vaccination with their care provider. They listed specific underlying conditions that put pregnant people at very high risk of experiencing serious complications from COVID-19:
    • Solid organ transplant recipients
    • Those with severe respiratory conditions including cystic fibrosis and severe asthma
    • Those who have homozygous sickle cell disease
    • Those receiving immunosuppression therapies sufficient to significantly increase risk of infection
    • Those receiving dialysis or with chronic kidney disease (stage 5)
    • Those with significant congenital or acquired heart disease
  • The JCVI also now advises that pregnant health care workers and pregnant workers in residential facilities can discuss the option of vaccination. In addition, they say that breastfeeding/chestfeeding parents should be offered vaccination if they are otherwise eligible.
  • The Royal College of Obstetricians & Gynecologists released a handout on COVID-19 vaccination and pregnancy (1/12/21). You can access this vaccine info sheet here.

Clinical Symptoms and Testing

  • COVID-19 symptoms are similar between pregnant and nonpregnant patients; however, some symptoms with infection appear to be less common during pregnancy, especially fever.
  • The U.S. PRIORITY study (Pregnancy CoRonavIrus Outcomes RegIsTrY) is an ongoing prospective nationwide study in the United States of pregnant or recently pregnant people. The most common symptoms in 594 symptomatic patients who tested positive for SARS-CoV-2 infection were cough (20%), sore throat (16%), body aches (12%), and fever (12%) (Afshar et al. 2020). Half of everyone had their symptoms resolve by 37 days, but symptoms lasted for ≥8 weeks in 25% of PRIORITY participants. In the PRIORITY study, 95% of participants were outpatients. The researchers are working to increase enrollment of Latina, Black, and Native American patients. These groups are currently underrepresented in the study (60% of study participants are White) which limits generalizability.
  • Data from the CDC that included more hospitalized pregnant people with COVID-19 show increased rates of symptoms (50% had cough, 32% had fever, 37% had muscle aches, 24% has chills, 43% had headache, 26% head shortness of breath, 28% had sore throat, 14% had diarrhea, 20% had N/V, 8% had abdominal pain, 13% had runny nose, 22% had new loss of taste or smell, 14% had fatigue, 2% had wheezing, and 4% had chest pain (Zambrano et al. 2020).
  • To treat fever and pain, acetaminophen (Tylenol) is preferred over NSAIDs (aspirin, ibuprofen/Motrin/Advil) because of possible worsening of symptoms with COVID-19 (Berghella and Hughes, 2020). Low-dose aspirin is still recommended for preeclampsia prevention as medically indicated, but may not be appropriate for pregnant and recently pregnant patients with suspected or confirmed COVID; care should be individualized (ACOG, 2020).
  • Systematic reviews suggest that the majority of pregnant people who test positive during universal screening are without symptoms (most asymptomatic, but some pre-symptomatic) (Berghella and Hughes, 2020).
  • COVID-19 diagnosis is done with nucleic acid amplification testing (NAAT), most commonly with a reverse-transcription polymerase chain reaction (RT-PCR) assay, which detects SARS-CoV-2 RNA from the upper respiratory tract. PCR tests are considered the gold standard for testing.
  • Antigen tests are another type of diagnostic test. They detect a specific protein in SARS-CoV-2. Antigen tests are sometimes used first, but these tests are less sensitive, so negative antigen tests should usually be confirmed with NAAT if there is clinical suspicion of COVID-19. The majority of rapid tests so far have been antigen tests; however, there are now rapid PCR-based tests available in some care settings.
  • False-negative tests are possible, so a negative RT-PCR test may need to be repeated if there is high clinical suspicion of COVID-19.
  • False-positives have also been reported, but they are thought to be less common than false-negatives.

Maternal Outcomes

  • There is no evidence that pregnancy increases the risk of getting infected with SARS-CoV-2
  • Definitions according to the National Institutes of Health:
    • Mild illness is considered symptoms without difficulty breathing or abnormal chest imaging
    • Moderate illness is evidence of lower respiratory disease by clinical assessment or imaging and a saturation of oxygen (SaO2) ≥94% on room air at sea level.
    • Severe illness is respiratory frequency >30 breaths per minute, SaO2 <94% on room air at sea level, ratio of arterial partial pressure of oxygen to fraction of inspired oxygen (PaO2/FiO2) < 300, or lung infiltrates >50%
    • Critical illness is respiratory failure, septic shock, and/or multiple organ dysfunction
  • Most (>90%) of people infected during pregnancy recover before they give birth and without needing hospitalization for COVID-19 (Berghella and Hughes, 2020). It is reassuring that the majority of pregnant people with COVID-19 either have no symptoms or mild illness that does not require hospitalization.
  • However, pregnancy has been shown to increase the risk of severe or critical COVID-19. Given the growing evidence, the CDC now includes pregnant people in its “increased risk” category for COVID-19 illness. Unfortunately, the evidence in limited by large amounts of missing data on pregnancy status, race/ethnicity, and info on symptoms and underlying medical conditions (Zambrano et al. 2020).
  • According to the latest U.S. surveillance data from the CDC (with over 400,000 symptomatic females of reproductive age), pregnant people with symptomatic COVID-19 appear to be at increased risk for ICU admission, invasive ventilation, extracorporeal membrane oxygenation (ECMO, a life support machine) and death compared to nonpregnant females of the same age with symptomatic COVID-19 (Zambrano et al. 2020). Still, the absolute risk of severe or critical illness and death for pregnant patients is low—even lower than the absolute risk of these outcomes during the H1N1 influenza pandemic (ACOG, 2020).
  • In the CDC analysis, the absolute risks for invasive ventilation and death for pregnant versus nonpregant people of the same age and sex were 2.9 versus 1.1 per 1,000 and 1.5 versus 1.2 per 1,000, respectively. ECMO was used rarely but at a higher rate with pregnancy (0.7 versus 0.3 per 1,000). The absolute risk of ICU admission was noticeably increased (10.5 versus 3.9 per 1,000); however, this may be due in part to differences in care management during pregnancy.
  • Remember, these absolute risks apply to people with lab-confirmed, symptomatic COVID-19; we don’t know if the risk of these outcomes is increased during pregnancy for people with asymptomatic infection or with symptoms that are so mild they do not seek medical care.
  • Risk factors for severe or critical COVID-19 during pregnancy are similar to the risk factors in the general population (Westnedge et al. 2021). They include age ≥35 years, BMI ≥30, hypertension, and diabetes (preexisting and gestational) (Allotey et al. 2020; ACOG, 2020).
  • Importantly, Black and Hispanic individuals who are pregnant are disproportionately affected by COVID-19—not because of their biology, but because of systemic racism creating inequitable opportunities for health.
  • Timing of birth with COVID-19 should be individualized. Importantly, COVID-19 infection is not an indication for Cesarean, induction, or operative vaginal birth. When possible, it’s best to wait to give birth until after testing negative. Then, there is less chance of passing the infection to health care workers and to the newborn in the postpartum period.
  • However, people with term pregnancies who have mild COVID-19 may wish to give birth sooner rather than later to avoid the risk of giving birth with more severe COVID-19 (should the disease worsen).
  • Severely ill patients at least 32 weeks of pregnancy with COVID-19 pneumonia may benefit from early birth. But it’s not clear whether giving birth improves the birthing person’s respiratory disease (Berghella and Hughes, 2020).
  • Maternal COVID-19 is linked to an increased risk of Cesarean. A report from the UK Obstetric Surveillance System (UKOSS) on pregnant people admitted to the hospital with confirmed COVID-19 in the UK found that 59% of people gave birth by Cesarean (Knight et al. 2020). About half of these were for maternal or fetal compromise and half were for other obstetric reasons (e.g., progress in labor, planned repeat Cesarean).
  • A large systematic review estimated that about 65% of pregnant people with suspected or confirmed COVID-19 gave birth by Cesarean (Allotey et al. 2020). Many of the studies in this review (24/77) came from China, where the Cesarean rate with COVID-19 was very high early in the pandemic.
  • U.S. surveillance data of pregnant people with laboratory-confirmed SARS-CoV-2 infection reported that among nearly 4,000 birthing people, the overall Cesarean rate was 34%, which is slightly higher than the U.S. Cesarean rate in 2019 (32%) (Berghella and Hughes, 2020).
  • Wider implications of the pandemic for maternal health include increased risk of mental health distress and intimate partner violence. Care providers should be on heightened alert for these issues and look for ways to help clients manage stress, anxiety, and depression.

Newborn Outcomes

  • Maternal COVID-19 has been linked to an overall increased risk of preterm birth, although individual countries have reported seeing decreased rates of preterm birth or no change in preterm birth rates.
  • A systematic review of 77 studies from more than a dozen different countries, including over 11,000 pregnant and recently pregnant people with suspected or confirmed COVID-19, estimated that about 17% of births were preterm (Allotey et al. 2020). This was a three times greater risk of preterm birth with COVID-19 compared to those without the disease. However, most of these preterm births were medically caused (iatrogenic). The spontaneous preterm birth rate was only 6%, which is similar to the rate observed before the pandemic. It’s thought that complications from COVID-19 (e.g., pneumonia) increase the risk of Cesarean and preterm birth because providers intervene in hopes of improving the maternal respiratory condition. However, there is no evidence that planned early birth improves maternal outcomes with severe or critical COVID-19 (Berghella and Hughes, 2020).
  • U.S. surveillance data of pregnant people with laboratory-confirmed SARS-CoV-2 infection reported that among 3,912 live births with known gestational age, 12.9% were preterm (<37 weeks) (Woodworth et al. 2020). This rate is higher than the reported 10.2% among the general U.S. population in 2019. Please see the Q&A section at the bottom of this newsletter for more discussion of pre-term birth rates during the pandemic.
  • The U.S. PRIORITY study has, so far, not detected a difference in poor outcomes, including preterm birth, NICU admission, and respiratory disease, between infants (n=263) born to birthing parents testing positive (n=179) versus those testing negative (n=84) (Flaherman et al. 2020). A study with more racial and ethnic diversity also did not detect a difference in poor outcomes (using a combined outcome of preterm birth, severe preeclampsia, or Cesarean for abnormal GHR) by maternal COVID-19 status (Adhikari et al. 2020).
  • There is no evidence suggesting an increased risk of congenital anomalies or any problems with the baby’s development.
  • There is also no evidence suggesting that infection in early pregnancy increases the risk of miscarriage. (Data on first and second trimesters are limited.)
  • Vertical transmission (transmission from the pregnant person to the baby before or during birth) has been reported in a few cases but it is thought to be rare. Researchers still do not understand the mechanisms by which vertical transmission occurs (Westnedge et al. 2021). A few placental infections and very early newborn infections have been reported; however, most placentas studied so far had no evidence of infection. Importantly, there is no evidence that the risk of vertical transmission is affected by mode of birth, method of feeding or rooming in. The vast majority (over 95%) of newborns born to infected parents have been asymptomatic or with only mild infection at birth. It is reassuring that severe or critical COVID-19 is rare with newborns (Westnedge et al. 2021).
  • A large U.S. observational study found that the rate of early newborn infection among infants born to a parent who tested positive was 3%; most of the infected babies were born to parents with no symptoms or mild symptoms (Adhikari et al. 2020).
  • There is no evidence that the risk of stillbirth increases with COVID-19 infection; however, the risk does appear to increase among patients hospitalized with a COVID-19 infection.
  • Analysis of hospitalization data from England did not show an increase in stillbirths in England during the pandemic when compared with the same months in the previous year (Stowe et al. 2020).
  • In the U.S., data from the CDC show a higher stillbirth rate among pregnant people hospitalized with COVID-19 compared to the overall population of pregnant people with lab-confirmed infection (3% versus 0.4%) (Panagiotakopoulos et al. 2020; Woodworth et al. 2020). For comparison, the overall rate of stillbirth in the U.S. is 0.6%. The increase in stillbirth among hospitalized COVID-19 patients may be related to maternal illness, medical intervention to treat COVID-19, and/or disruptions in prenatal care during the pandemic.
  • There have been reports of problems with placental function from COVID-19 infection. However, more data is needed before we know how widespread a problem this is, and whether it’s clinically significant.

Treatment

  • Corticosteroid use to help prevent preterm birth is likely safe for pregnant people with COVID-19, and corticosteroid use for severe or critical maternal COVID-19 may also be beneficial (Westnedge et al. 2021).
  • ACOG recommends that dexamethasone, a corticosteroid, be used for pregnant people with COVID-19 who are receiving supplemental oxygen or are mechanically ventilated, and that dexamethasone should not be withheld for treatment of COVID-19 due to pregnancy status.
  • Similarly, UpToDate guidance for clinicians advises that “In pregnant women who meet criteria for use of glucocorticoids for maternal treatment of COVID-19 and also meet criteria for use of antenatal corticosteroids for fetal maturity, we suggest administering the usual doses of dexamethasone (four doses of 6 mg given intravenously 12 hours apart) to induce fetal maturation and continue dexamethasone to complete the course of maternal treatment for COVID-19 (6 mg orally or intravenously daily for 10 days or until discharge, whichever is shorter).”
  • The evidence for dexamethasone treatment comes from the RECOVERY trial, a large, multicenter, RCT for patients hospitalized with COVID-19 in the U.K. (RECOVERY Collaborative Group et al. 2020). The trial showed that dexamethasone resulted in lower 28-day mortality among people receiving either mechanical ventilation or oxygen but not among those receiving no respiratory support. Even though only six pregnant people were included in the trial, guidance supports dexamethasone for use with infected pregnant people who are receiving supplemental oxygen or are mechanically ventilated because of possible life-saving benefits.
  • Pregnancy is a hypercoagulable state (meaning there is an increased tendency toward blood clotting), so people who are pregnant or in the postpartum period have increased risk of thromboembolism (a blood clot that is carried by the blood stream and plugs a blood vessel) compared with nonpregnant people (ACOG, 2020). COVID-19 is also linked to increased blood clotting and increased risk of thromboembolism, especially in ICU patients. Therefore, recommendations are that pregnant patients hospitalized with severe or critical COVID-19 should be treated with prophylactic-dose anticoagulation, if there are no contraindications to its use (ACOG, 2020; Berghella and Hughes, 2020). Clinicians should also have a low threshold for investigating possible thromboembolic events in COVID-19 patients during pregnancy and postpartum (Westnedge et al. 2021). Please see the Q&A section at the bottom of this newsletter for more discussion of anticoagulant drugs.
  • Remdesivir, an antiviral medication, is recommended for pregnant patients who would otherwise be candidates for the treatment. It has been used with severely ill pregnant patients without causing harm to the fetus (Berghella and Hughes, 2020).

Giving Birth

  • ACOG guidelines suggest, “In both the inpatient and outpatient settings, it is recommended that the number of visitors be reduced to the minimum necessary, for example, those essential for the pregnant individual’s well-being (emotional support persons).” Importantly, they say, “Labor, delivery, and postpartum support may be especially important to improve outcomes for individuals from communities traditionally underserved or mistreated within the health care system. In considering visitation policies, institutions should be mindful of how restrictions might differentially and negatively affect these communities, which in many areas are also disproportionately affected by COVID-19.”
  • Professional guidelines acknowledge that it may not be feasible to wear a mask during labor, especially during second stage labor (ACOG, 2020). Wearing a mask could make pushing difficult and forceful exhalation may also make the mask significantly less effective. For this reason, those caring for birthing people should use appropriate PPE.
  • Delayed cord clamping is still best practice when the birthing parent has COVID-19 (ACOG, 2020). The cord should remain unclamped for up to five minutes or when cord pulsation ceases. There is no evidence that delayed cord clamping increases the risk of giving the virus to the baby, and there are substantial known risks to early cord clamping. The care provider should wear appropriate PPE.

Rooming in and Infant Feeding

  • There are many established benefits to rooming in, including increased success breastfeeding and parent-infant bonding. Studies have not found a difference in the rate of transmission when newborns are separated from infected parents versus kept together in the same room. Guidelines now state that newborns should “ideally” be kept together with their infected parent, and that “Decisions about temporary separation should be made in accordance with the mother’s wishes.” (ACOG, 2020).
  • Birthing parents with COVID-19 should be encouraged to breastfeed/chestfeed, but should wear PPE (Westnedge et al. 2021). It is not known whether the virus can be transmitted through breastmilk. One case report detected SARS-CoV-2 RNA in breastmilk, but the viral particles may not have been infectious; most breastmilk samples from positive parents have been negative.
  • Healthy, uninfected birthing parents and newborns are advised to consider early hospital discharge after birth (after 1 day with uncomplicated vaginal births and after 2 days with Cesarean births depending on recovery status) (ACOG, 2020).

Professional Guidance and Clinical Recommendations

  • Several professional organizations have issued guidance on pregnancy issues during the pandemic. You can access professional guidance at acog.orgSMFM.org, and rcog.org.uk.
  • Also, UpToDate.com has made their COVID-19 content free. They have a page devoted to COVID-19 and pregnancy.

Q & A Section

Question: Do we know what the overall pre-term birth rate was in the U.S. for 2020, and how that might compare to other years?

Answer: No, the most recent year of birth data from the U.S. Centers for Disease Control (CDC) is 2019. The CDC National Center for Health Statistics (NCHS) released their latest data brief (No. 387) in October 2020 with key findings from the 2019 data. The overall rate of preterm birth rose to 10.23% in 2019, an increase over the 2018 rate of 10.02%.

We don’t know yet if the U.S. preterm birth rate rose in 2020, although early findings suggest that it may have. The CDC has been collecting info on pregnancy and infant outcomes among pregnant people with lab-confirmed infections through SET-NET (the Surveillance for Emerging Threats to Mothers and Babies Network). Among 3,912 live births to infected parents, 12.9% were preterm (<37 weeks) (Woodworth et al. 2020). As you can see, this is higher than the U.S. preterm birth rate among the general population in 2018 and 2019, and if enough pregnant people experienced infection, this could possibly contribute to a higher preterm birth rate in 2020.

Individual studies have been mixed on whether they found a difference in preterm births during the pandemic. Decreases in preterm births have been reported in several European countries, sometimes alongside increases in stillbirth. But even within countries, the impact of the pandemic on preterm birth likely varies in sub-populations based on social and economic factors.

Question: I have a history of COVID in early pregnancy, and now my doctor is recommending that I take either aspirin or an anticoagulant for the rest of pregnancy. Is there any research on this or guidelines to support this practice?

Answer: We have not seen any evidence to support the prophylactic (preventative) use of aspirin among pregnant people with a history of COVID-19 earlier in pregnancy but without other clinical indications for the treatment. However, recommendations mention that aspirin should continue to be offered to pregnant and postpartum parents as medically indicated during the pandemic (ACOG, 2020). Perhaps your doctor is recommending aspirin for a non-COVID related medical indication? Low-dose aspirin is most commonly recommended during pregnancy to pregnant people at moderate to high risk of preeclampsia.

As we mentioned earlier in this newsletter, aspirin may not be appropriate for pregnant people with suspected or confirmed COVID-19 because of evidence that NSAIDs (including aspirin) potentially worsen COVID symptoms.

We are also not aware of any evidence (yet) to support thromboprophylaxis with anticoagulants among pregnant people with a history of COVID-19 earlier in pregnancy but without other clinical indications for the treatment. People with active COVID-19 infections during pregnancy (particularly with severe or critical disease) may benefit from anticoagulation treatment, but the treatment is only recommended for those who are hospitalized because of their COVID-19 disease (Berghella and Hughes, 2020). People hospitalized because of their COVID-19 infections may be advised to continue thromboprophylaxis for 10 days following hospital discharge or longer if they remain ill from their infection. But if you had COVID-19 in early pregnancy and it did not require hospitalization, then your doctor may be recommending anticoagulants because you have non-COVID related risk factors for blood clots (also known as venous thromboembolisms, or VTEs).

Whenever care providers recommend intervention, you should always feel empowered to ask them if their advice is based on a research study, a clinical guideline, or their professional medical opinion. Also, keep in mind that as the pandemic progresses, new research may come out that provides us with new insights on this topic.

This concludes the research update for January 21, 2021. We hope you found it helpful! Our next research update will come out in March 2021.

If you would like to submit a follow-up question for our consideration to include in upcoming newsletters, you can submit your question here.

Sincerely,

The Research Team at Evidence Based Birth®


References

Adhikari, E. H., Moreno, W., Zofkie, A. C., et al. Pregnancy Outcomes Among Women With and Without Severe Acute Respiratory Syndrome Coronavirus 2 Infection. JAMA Netw Open. 2020;3(11):e2029256. Click here.

Afshar, Y., Gaw, S. L., Flaherman, V. J., et al. (2020). Clinical Presentation of Coronavirus Disease 2019 (COVID-19) in Pregnant and Recently Pregnant People. Obstet Gynecol. 2020 Dec;136(6):1117-1125. Click here.

Allotey, J., Stallings, E., Bonet, M., et al… for PregCOV-19 Living Systematic Review Consortium (2020). Clinical manifestations, risk factors, and maternal and perinatal outcomes of coronavirus disease 2019 in pregnancy: living systematic review and meta-analysis. BMJ (Clinical research ed.), 370, m3320. Click here.

American College of Obstetricians and Gynecologists (2020). COVID-19 FAQs for obstetricians-gynecologists, obstetrics. Washington, DC: ACOG. Available at: https://www.acog.org/clinical-information/physician-faqs/covid-19-faqs-for-ob-gyns-obstetrics. Retrieved January 7, 2020.

Berghella, V. and Hughes, B. (2020). UpToDate: Coronavirus disease 2019 (COVID-19): Pregnancy Issues and Antenatal care. Click here.

Flaherman, V. J., Afshar, Y., Boscardin, W. J., et al. (2020). Infant Outcomes Following Maternal Infection With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2): First Report From the Pregnancy Coronavirus Outcomes Registry (PRIORITY) Study, Clinical Infectious Diseases, ciaa1411. Click here.

Knight, M., Bunch, K., Vousden, N., et al. Characteristics and outcomes of pregnant women admitted to hospital with confirmed SARS-CoV-2 infection in UK: national population based cohort study. BMJ 2020; 369:m2107. Click here.

Panagiotakopoulos, L., Myers, T. R., Gee, J., et al. (2020). SARS-CoV-2 Infection Among Hospitalized Pregnant Women: Reasons for Admission and Pregnancy Characteristics — Eight U.S. Health Care Centers, March 1–May 30, 2020. MMWR Morb Mortal Wkly Rep 2020;69:1355–1359. Click here.

RECOVERY Collaborative Group, Horby, P., Lim, W. S., et al. (2020). Dexamethasone in Hospitalized Patients with Covid-19 – Preliminary Report. N Engl J Med. 2020 Jul 17:NEJMoa2021436. Click here.

Stowe, J., Smith, H., Thurland, K., et al. (2020). Stillbirths During the COVID-19 Pandemic in England, April-June 2020. JAMA 2020. Click here.

Wastnedge, E. A. N., Reynolds, R. M., van Boeckel, S. R., et al. (2021). Pregnancy and COVID-19. Physiol Rev. 2021 Jan 1;101(1):303-318. Click here.

Woodworth, K. R., CDC COVID-19 Response Pregnancy and Infant Linked Outcomes Team, COVID-19 Pregnancy and Infant Linked Outcomes Team (PILOT), et al. (2020). Birth and Infant Outcomes Following Laboratory-Confirmed SARS-CoV-2 Infection in Pregnancy – SET-NET, 16 Jurisdictions, March 29-October 14, 2020. MMWR Morb Mortal Wkly Rep. 2020 Nov 6;69(44):1635-1640. Click here.

Zambrano, L. D., Ellington, S., Strid, P., CDC COVID-19 Response Pregnancy and Infant Linked Outcomes Team, et al. (2020). Update: Characteristics of Symptomatic Women of Reproductive Age with Laboratory-Confirmed SARS-CoV-2 Infection by Pregnancy Status – United States, January 22-October 3, 2020. MMWR Morb Mortal Wkly Rep. 2020 Nov 6;69(44):1641-1647. Click here.

Covid-19 e morte fetal no primeiro trimestre

 

Texto de Melania Amorim

@melania44 

・・・
COVID-19 e morte fetal no primeiro trimestre
A doença por coronavírus 2019 (COVID-19) é causada pela infecção do trato respiratório por SARS-CoV-2, que sobrevive nos tecidos durante o curso clínico da infecção, mas há evidências limitadas de infecção placentária e transmissão vertical de SARS-CoV-2 . O impacto da COVID-19 na gravidez de primeiro trimestre permanece pouco compreendido. Além disso, não se sabe por quanto tempo o SARS-CoV-2 pode sobreviver na placenta.
Aqui, relatamos o caso de uma mulher grávida no primeiro trimestre que apresentou resultado positivo para SARS-CoV-2 com 8 semanas de gestação, embora seu curso clínico tenha sido assintomático. Na 13ª semana de gestação, seu esfregaço de garganta testou negativo para SARS-CoV-2, mas o RNA viral foi detectado na placenta e as proteínas Spike (S) (S1 e S2) foram imunolocalizadas no citotrofoblasto e células sincitiotrofoblastas das vilosidades placentárias.
Histologicamente, as vilosidades eram geralmente avasculares com deposição de fibrina peri-vilositária e em algumas áreas a camada de sincitiotrofoblasto parecia lisada. A decídua também apresentava deposição de fibrina com extensa infiltração leucocitária sugestiva de inflamação.
O SARS-CoV-2 cruzou a barreira placentária, pois o RNA viral foi detectado no líquido amniótico e as proteínas S foram detectadas na membrana fetal. A ultrassonografia revelou edema subcutâneo extenso com derrame pleural sugestivo de hidropisia fetal e a ausência de atividade cardíaca indicou morte fetal.
Este é o primeiro estudo a fornecer evidências concretas de infecção placentária persistente de SARS-CoV-2 e sua transmissão congênita associada com hidropisia fetal e morte fetal intrauterina no início da gravidez.

Infant Outcomes Following Maternal Infection with SARS-CoV-2: First Report from the PRIORITY Study

Nesse recente estudo (PRIORITY), disponível na página neonatal www.paulomargotto.com.br, com uma coorte de 263 bebês, incluindo 179 e 84, respectivamente, nascidos de mães com teste positivo ou negativo para SARS CoV-2, mostrou que o risco de infecção pelo bebê foi de 1,1% (e os sintomas foram mínimos). Sem complicações nas 6-8semanas. Na discussão desse estudo trouxemos informações de uma das maiores coorte dos Estados Unidos de neonatos nascidos de mães com teste positivo para SARS-CoV-2 no momento do parto e que foram subsequentemente acompanhadas com testes seriados e clinicamente até 1 mês de vida. Oitenta e dois neonatos (68%) completaram o acompanhamento no dia 5–7 de vida. Dos 82 neonatos, 68 (83%) ficaram com as mães. Todas as mães foram autorizadas a amamentar; com 5 a 7 dias de vida, 64 (78%) ainda estavam amamentando. 79 (96%) de 82 neonatos tiveram uma repetição da PCR em 5–7 dias de vida, que foi negativa em todos; 72 (88%) neonatos também foram testados com 14 dias de vida e nenhum foi positivo. Nenhum dos neonatos apresentou sintomas de COVID-19. Assim, o o Alojamento Conjunto com a mãe e a amamentação são seguros se associados à educação adequada dos pais sobre práticas seguras de controle de infecção, como o uso de máscaras cirúrgicas em todos os momentos e a higienização frequente das mãos.

 

Abstract

Infant outcomes after maternal SARS-CoV-2 infection are not well-described. In a prospective U.S. registry of 263 infants born to mothers testing positive or negative for SARS-CoV-2, SARS-CoV-2 status was not associated with birth weight, difficulty breathing, apnea or upper or lower respiratory infection through 8 weeks of age.

Keywords: COVID-19; Newborn; Pregnancy; SARS-CoV-2.